Anemia

Anemia and iron deficiency are prevalent in heart failure with mildly reduced ejection fraction and may worsen mortality and rehospitalization outcomes.

Treatment with intravenous iron therapy proves more efficacious than oral or no iron therapy in improving hemoglobin in pediatric patients admitted with IBD and IDA.

When the current recommended diagnostic algorithm was used in clinical practice, antibody testing was required in half of patients with suspected HIT.

Oral iron supplements did not significantly differ in increasing hemoglobin and ferritin levels, but the every-other-day oral iron proved more effective than daily use.

This clinical quiz will test your knowledge of iron deficiency anemia, focused on the gastrointestinal evaluation of anemia based on recommendations from the AGA's 2020 guidelines.

Our March 2024 month-in-review in hematology features updates to the anemia pipeline, the latest research in sickle cell disease, and the role of SGLT2 inhibition on hematologic outcomes.

Iron-deficient patients on an SGLT2 inhibitor at baseline experienced greater increases in hemoglobin levels with ferric derisomaltose compared with those not taking one.

Vadadustat tablets are now approved for the treatment of anemia due to CKD in adults who have been receiving dialysis for ≥ 3 months.

A new analysis summarized evidence on the effects of allogeneic HSCT on SCD-related organ dysfunction in pediatric and adult patients with SCD.

A posthoc analysis of two phase 3 trials identified multiple independent factors associated with better response to vadadustat in patients with anemia.

A study in China identified a negative and non-linear relationship between hemoglobin levels and a renal composite end point in patients with DKD.

Measurement of reticulocyte hemoglobin equivalent is cost-effective and could be a useful marker of iron deficiency in acute decompensated heart failure.

Iron deficiency, independent of anemia, may be a potentially modifiable target to improve patient-reported outcomes after kidney transplantation.

A cross-sectional analysis of nine low- and middle-income countries revealed few statistically significant associations between anemia and early childhood development.

Iptacopan monotherapy improved hematologic outcomes in both anti-C5–treated patients with persistent anemia and those not treated with complement inhibitors across two phase 3 trials.

Iron deficiency marks more than a comorbidity in heart failure, with adverse manifestations, including anemia and a higher risk of mortality, influencing the clinical trajectory of patients with HFrEF.

Initiation of SGLT2 inhibitors reduced the risk of composite anemia outcomes, compared with GLP-1 RA, among patients with type 2 diabetes and CKD.

Introduction of curated materials to assist clinicians was linked to better rates of screening and treatment of iron deficiency anemia among patients with heart failure.

More than half of older patients admitted to geriatric units in France had iron deficiency, including patients without anemia.

A meta-analysis of four RCTs found Iron isomaltoside ferumoxytol is both effective and safe to treat iron deficiency anemia.

Voxelotor decreases oxygen extraction fraction and cerebral blood flow towards levels observed in healthy children.

No concerning patterns of long-term or increasing opioid use were observed within 3 years after first opioid prescription in opioid-naive children with SCD.

Hearing loss was more prevalent among children and adults with sickle cell disease and its traits compared to matched controls with normal hemoglobin.

Over the study period, pain screening procedures were integrated within routine clinical visits and providers’ workflow in sickle cell disease care.

Microalbuminuria and low body iron levels displayed a significant association with pediatric hearing loss independently.

The approval provides patients with the first-ever treatment option for severe frostbite to prevent the amputation of fingers or toes.

Mitapivat treatment was linked to long-term improvements in key markers of iron homeostasis and erythropoiesis in an analysis of the phase 3 ACTIVATE trial.

Non-breast milk-fed infants received more iron on average each day than breast-milk-fed infants, but experienced a higher rate of iron deficiency.

A new analysis cites relatively high hemoglobin levels as a protective factor for bone quality in patients with type 2 diabetes.

A trial comparing iron supplementation methods for postpartum maternal fatigue found similar fatigue reduction regardless of treatment type.